Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia

Documenti analoghi

• Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax offers a Therapeutic Strategy for Acute Myeloid Leukemia
  di: Eide, Christopher A., et al.
  Pubblicazione: (2020)
• Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
  di: Rosenberg, Mara W., et al.
  Pubblicazione: (2020)
• Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
  di: White, Brian S., et al.
  Pubblicazione: (2021)
• Recurrent cyclin D2 mutations in myeloid neoplasms
  di: Khanna, V, et al.
  Pubblicazione: (2017)
• Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies
  di: Kurtz, Stephen E., et al.
  Pubblicazione: (2017)